Helping Patients Navigate the Voriconazole Shortage

When a patient with invasive aspergillosis or another serious mold infection can't fill their Voriconazole prescription, it's not just an inconvenience — it's a clinical emergency. Treatment gaps in antifungal therapy can lead to disease progression, treatment failure, and potentially fatal outcomes.

As a provider, you're in a unique position to help. This guide offers practical, actionable steps to help your patients find Voriconazole and maintain continuity of care during ongoing supply disruptions.

Current Availability Overview

As of early 2026, the Voriconazole supply picture varies by formulation:

• Oral tablets (50 mg, 200 mg): Most available formulation. Multiple generic manufacturers are active. Spot shortages at individual pharmacies are common, but stock is generally findable with effort.
• Oral suspension (40 mg/mL): Limited availability due to fewer manufacturers. Compounding may be necessary in some cases.
• IV injection (200 mg vials): Most affected by shortages. Hospital pharmacies and specialty distributors tend to have better access than retail chains.

For the full supply timeline and context, see our provider-focused shortage update.

Why Patients Can't Find Voriconazole

Understanding the root causes helps you anticipate and address access problems:

• Manufacturing consolidation: A small number of generic manufacturers (Teva, Sandoz, Aurobindo, Dr. Reddy's) supply the entire U.S. market. A disruption at any single facility creates widespread shortages.
• Distribution inequity: Large chain pharmacies and hospital systems often receive priority allocations, leaving independent and smaller pharmacies undersupplied.
• Increasing demand: The expanding population of immunocompromised patients — from CAR-T therapy, transplantation, and biologic use — continues to drive higher antifungal utilization.
• Patient navigation barriers: Many patients don't know they can transfer prescriptions, use specialty pharmacies, or access tools like Medfinder. They assume if their pharmacy is out, the drug is simply unavailable.

What Providers Can Do: 5 Actionable Steps

Step 1: Direct Patients to Medfinder

Medfinder for Providers is a real-time pharmacy stock lookup tool. You can use it during clinic visits to identify pharmacies near the patient that currently have Voriconazole in stock. Share the link with patients so they can check availability independently.

This single step can save patients hours of phone calls and prevent dangerous gaps in therapy.

Step 2: Send Prescriptions to Pharmacies With Confirmed Stock

Rather than sending a prescription to the patient's usual pharmacy and hoping for the best, check availability first and send the prescription directly to a pharmacy that has the medication. This is especially important for new starts and patients transitioning from IV to oral therapy.

Step 3: Leverage Specialty Pharmacy Channels

Specialty pharmacies that serve oncology, transplant, and infectious disease patients often maintain more reliable Voriconazole inventory. Many insurance plans have a designated specialty pharmacy — check with the patient's insurer. If your practice doesn't already have specialty pharmacy relationships, consider establishing them for antifungals and other shortage-prone medications.

Step 4: Consider Formulation Flexibility

If one formulation is unavailable, another may work:

• Oral tablets are the most available formulation
• Oral suspension can substitute when tablets aren't available (comparable bioavailability)
• IV-to-oral conversion is straightforward given ~96% oral bioavailability — transition patients to oral therapy as soon as clinically appropriate to preserve IV supply

Document the rationale for any formulation change and recheck therapeutic drug monitoring (TDM) after switching.

Step 5: Have a Backup Plan Ready

For patients on chronic Voriconazole therapy, proactively identify an alternative agent in case of a supply disruption. Document the backup plan in the chart so any covering provider can act quickly if needed. Common alternatives include:

• Isavuconazole (Cresemba) — non-inferior for invasive aspergillosis, fewer interactions
• Posaconazole (Noxafil) — broad-spectrum, good prophylaxis data
• Itraconazole (Sporanox) — less potent for aspergillosis but available and affordable as a generic

See the full comparison in our alternatives guide.

Prescribing Alternatives During Shortages

When switching to an alternative antifungal, key considerations include:

• Spectrum of activity: Ensure the alternative covers the patient's documented or suspected pathogen. Isavuconazole and Posaconazole cover Aspergillus; Posaconazole and Amphotericin B also cover Mucorales.
• Drug interactions: Review the patient's full medication list. Isavuconazole has fewer CYP450 interactions than Voriconazole, which may simplify management in patients on complex regimens.
• Route of administration: Patients who need IV therapy and can't access IV Voriconazole may benefit from IV Isavuconazole (no SBECD vehicle, safe in renal impairment) or liposomal Amphotericin B.
• Insurance and prior authorization: Brand-name alternatives (Cresemba, Noxafil) typically require prior authorization. Initiate this proactively when you anticipate a potential switch. Document the shortage as medical justification.
• TDM: Voriconazole and Posaconazole benefit from therapeutic drug monitoring. Isavuconazole has more predictable pharmacokinetics and TDM is less commonly performed but may still be useful.

Workflow Tips for Your Practice

• Build shortage awareness into refill workflows. Flag patients on Voriconazole for proactive check-ins 1-2 weeks before refill dates.
• Maintain a specialty pharmacy contact list. Have phone numbers and fax numbers for 2-3 specialty pharmacies that stock antifungals ready in your clinic.
• Educate support staff. Ensure nurses, medical assistants, and pharmacy liaisons know about Medfinder and can help patients navigate availability.
• Communicate with hospital pharmacy. If you have inpatients on IV Voriconazole, coordinate with the hospital pharmacist on discharge planning to ensure a smooth transition to outpatient oral therapy with confirmed supply.
• Document shortage-related decisions. Note in the chart when formulation changes or alternative agent switches are driven by supply issues rather than clinical factors. This supports continuity of care and insurance appeals.

Cost Resources for Your Patients

Voriconazole is expensive, and cost non-adherence is a real risk. Point patients toward:

• Discount cards: GoodRx, SingleCare, and RxSaver can reduce generic Voriconazole costs to $80–$250/month
• Pfizer RxPathways: 1-844-989-7284 for brand Vfend assistance
• NeedyMeds and RxAssist: Comprehensive patient assistance program directories
• Our patient guide: How to Save Money on Voriconazole

For a provider-specific guide to helping patients save, see How to Help Patients Save Money on Voriconazole.

Final Thoughts

The Voriconazole shortage requires providers to be proactive, flexible, and resourceful. By leveraging tools like Medfinder for Providers, maintaining specialty pharmacy relationships, and having alternative agent plans documented, you can minimize treatment disruptions and protect your patients' outcomes.

The shortage may be ongoing, but with the right systems in place, your patients don't have to go without treatment.